Abstract
Background
SPECT improves diagnostic specificity of Technetium-99m pyrophosphate (PYP) scintigraphy. Diagnostic performance of PYP data, reconstructed as either chest or cardio-focal SPECT is not known.
Methods
In this quality assurance study, blinded evaluation of PYP SPECT/CT data from 102 Caucasian patients (mean age 76 ± 11 years, 67% men) was performed by two readers. Reader 1 reviewed planar and PYP chest SPECT, while reader 2 reviewed planar and cardio-focal PYP SPECT. Demographic, clinical, and other testing data were obtained from the electronic medical records.
Results
A total of 41 patients (40%) were considered positive based on myocardial uptake on chest PYP SPECT. Of these, 98% of the patients had a Perugini score ≥ 2 on planar imaging. There was good agreement between the two readers for visual score ≥ 2 (k = .88, P < .001) and excellent agreement for myocardial uptake on tomographic imaging (98%, P < .001). Only one study was categorized as false negative by cardio-focal SPECT reconstruction. Non-diffuse myocardial uptake was identified in 22% of those with a positive PYP SPECT.
Conclusion
When read by experienced readers, chest and cardio-focal reconstruction of PYP SPECT have comparable diagnostic performance. A substantial proportion of patients with a positive PYP SPECT have a non-diffuse distribution of PYP. Given the possibility of misclassification of non-diffuse myocardial uptake on cardio-focal reconstruction alone, chest reconstruction of PYP scintigraphy should be strongly considered.
Abbreviations
- CA:
-
Cardiac amyloidosis
- PYP:
-
Technetium-99m pyrophosphate
- ATTR:
-
Transthyretin amyloidosis
- FOV:
-
Field of view
- CZT:
-
Cadmium-zinc-telluride
- LV:
-
Left ventricular
- H/CL:
-
Heart to contralateral lung
- CKD:
-
Chronic kidney disease
- LVEF:
-
Left ventricular ejection fraction
- IVSd:
-
Interventricular septum thickness in diastole
References
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065‐123.
Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate. JACC 2021;14:1221‐31.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.
Sperry BW, Burgett E, Bybee KA, McGhie AI, O’Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol 2020;27:1802‐7.
Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls. J Nucl Cardiol 2021;28:104‐11.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2021;28:1769‐74.
Urbain J-L, Richardson J, Ross A, Khider M, Akincioglu C. CANM cardiac amyloid PYP imaging guidelines. Can Assoc Nucl Med.
Asif T, Gupta A, Murthi M, Soman P, Singh V, Malhotra S. Echocardiographic indices of left ventricular function and filling pressure are not related to blood pool activity on pyrophosphate scintigraphy. J Nucl Cardiol 2022. https://doi.org/10.1007/s12350-022-02989-4.
Asif T, Vij A, Radzik B, Stern H, Simples P, Ghadiali Q, et al. Multimodality imaging for diagnosis of subclinical hereditary transthyretin cardiac amyloidosis. J Nucl Cardiol 2021. https://doi.org/10.1007/s12350-021-02865-7.
Tamarappoo B, Otaki Y, Manabe O, Hyun M, Cantu S, Arnson Y, et al. Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2020;27:28‐37.
Tilkemeier PL, Bourque J, Doukky R, Sanghani R, Weinberg RL. ASNC imaging guidelines for nuclear cardiology procedures: Standardized reporting of nuclear cardiology procedures. J Nucl Cardiol 2017;24:2064‐128.
Disclosure
Cigdem Akincioglu received research support from Pfizer; Mukunthan Murthy had none; Jonathan Romsa had none to disclose; James Warrington had— none to disclose; Saurabh Malhotra received research support from ASNC/Pfizer Inc., is one of the members in Speakers Bureau for Pfizer Inc. and Alnylam, and is an advisory board member for Pfizer, Alnylam, and BridgeBio.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
The authors have also provided an audio summary of the article, which is available to download as ESM, or to listen to via the JNC/ASNC Podcast.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Akincioglu, C., Murthi, M., Romsa, J. et al. Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study. J. Nucl. Cardiol. 30, 2607–2614 (2023). https://doi.org/10.1007/s12350-023-03256-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-023-03256-w